

# William T Abraham

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9949656/william-t-abraham-publications-by-year.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185 papers	9,901 citations	43 h-index	97 g-index
191 ext. papers	12,936 ext. citations	8 avg, IF	6.09 L-index

#	Paper	IF	Citations
185	Age-Related Outcomes After Transcatheter Mitral Valve Repair in Patients With Heart Failure: Analysis From COAPT.. <i>JACC: Cardiovascular Interventions</i> , <b>2022</b> , 15, 397-397	5	1
184	Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation.. <i>Heart</i> , <b>2022</b> ,	5.1	3
183	Remote Speech Analysis in the Evaluation of Hospitalized Patients With Acute Decompensated Heart Failure.. <i>JACC: Heart Failure</i> , <b>2022</b> , 10, 41-49	7.9	3
182	Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial.. <i>European Heart Journal</i> , <b>2022</b> ,	9.5	1
181	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week.. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 504-510	15.1	0
180	Dose-limiting, adverse event-associated bradycardia with $\beta$ -blocker treatment of atrial fibrillation in the GENETIC-AF trial.. <i>Heart Rhythm</i> <b>2022</b> , 3, 40-49	1.5	
179	Direct Interstitial Decongestion in an Animal Model of Acute-on-Chronic Ischemic Heart Failure. <i>JACC Basic To Translational Science</i> , <b>2021</b> , 6, 872-881	8.7	0
178	Right Ventricular-Pulmonary Arterial Coupling in Patients With HF Secondary MR: Analysis From the COAPT Trial. <i>JACC: Cardiovascular Interventions</i> , <b>2021</b> , 14, 2231-2242	5	6
177	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , <b>2021</b> , 42, 700-710	9.5	35
176	3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 1029-1040	15.1	36
175	Defining a Clinically Important Change in 6-Minute Walk Distance in Patients With Heart Failure and Mitral Valve Disease. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e007564	7.6	3
174	Remote Hemodynamic-Guided Therapy of Patients With Recurrent Heart Failure Following Cardiac Resynchronization Therapy. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e017619	6	6
173	Association of Effective Regurgitation Orifice Area to Left Ventricular End-Diastolic Volume Ratio With Transcatheter Mitral Valve Repair Outcomes: A Secondary Analysis of the COAPT Trial. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 427-436	16.2	14
172	Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to MitraClip in the COAPT Trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2021</b> , 14, e010300	6	7
171	Effect of Mitral Valve Gradient After MitraClip on Outcomes in Secondary Mitral Regurgitation: Results From the COAPT Trial. <i>JACC: Cardiovascular Interventions</i> , <b>2021</b> , 14, 879-889	5	5
170	Transvenous Phrenic Nerve Stimulation for Treatment of Central Sleep Apnea: Five-Year Safety and Efficacy Outcomes. <i>Nature and Science of Sleep</i> , <b>2021</b> , 13, 515-526	3.6	9
169	Feasibility of remote speech analysis in evaluation of dynamic fluid overload in heart failure patients undergoing haemodialysis treatment. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 2467-2472	3.7	4

168	Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 1334-1349	6.1	1
167	Early Reduction in Ambulatory Pulmonary Artery Pressures After Initiation of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008212	7.6	2
166	Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 1-12	7.9	10
165	A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 175-185	12.3	16
164	Wireless Hemodynamic Monitoring in Patients with Heart Failure. <i>Current Heart Failure Reports</i> , <b>2021</b> , 18, 12-22	2.8	3
163	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. <i>American Heart Journal</i> , <b>2021</b> , 237, 45-53	4.9	2
162	Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. <i>Circulation</i> , <b>2021</b> , 144, 1265-1267	16.7	2
161	Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the Arg389Arg Genotype. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2021</b> , 14, e009591	6.4	1
160	Impact of Diabetes on Outcomes After Transcatheter Mitral Valve Repair in Heart Failure: COAPT Trial. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 559-567	7.9	0
159	Patient monitoring across the spectrum of heart failure disease management 10 years after the CHAMPION trial. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 3472-3482	3.7	5
158	Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 931-956	15.1	6
157	Relationship Between Residual Mitral Regurgitation and Clinical and Quality-of-Life Outcomes After Transcatheter and Medical Treatments in Heart Failure: COAPT Trial. <i>Circulation</i> , <b>2021</b> , 144, 426-437	16.7	12
156	Left Ventricular Global Longitudinal Strain as a Predictor of Outcomes in Patients with Heart Failure with Secondary Mitral Regurgitation: The COAPT Trial. <i>Journal of the American Society of Echocardiography</i> , <b>2021</b> , 34, 955-965	5.8	0
155	Prognostic Importance of Health Status Versus Functional Status in Heart Failure and Secondary Mitral Regurgitation. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 684-692	7.9	3
154	Pulmonary Artery Pressure Monitoring Effectively Guides Management to Reduce Heart Failure Hospitalizations in Obesity. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 784-794	7.9	1
153	Sex-Specific Outcomes of Transcatheter Mitral-Valve Repair and Medical Therapy for Mitral Regurgitation in Heart Failure. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 674-683	7.9	5
152	Conceptual Considerations for Device-Based Therapy in Acute Decompensated Heart Failure: DRIPS. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006731	7.6	11
151	Optimizer Smart in the treatment of moderate-to-severe chronic heart failure. <i>Future Cardiology</i> , <b>2020</b> , 16, 13-25	1.3	9

150	Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient-level database analysis. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1803-1813	12.3	27
149	The Use of MitraClip in Secondary Mitral Regurgitation and Heart Failure. <i>Cardiovascular Revascularization Medicine</i> , <b>2020</b> , 21, 1606-1612	1.6	1
148	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , <b>2020</b> , 41, 2109-2117	9.5	42
147	Health Status Changes and Outcomes in Patients With Heart Failure and Mitral Regurgitation: The COAPT Trial. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2099-2106	15.1	15
146	In-Hospital Management of Sleep Apnea During Heart Failure Hospitalization: A Randomized Controlled Trial. <i>Journal of Cardiac Failure</i> , <b>2020</b> , 26, 705-712	3.3	4
145	Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 1-13	15.1	41
144	Future research prioritization in cardiac resynchronization therapy. <i>American Heart Journal</i> , <b>2020</b> , 223, 48-58	4.9	7
143	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 432-441	16.2	22
142	The clinical characteristics of lower extremity lymphedema in 440 patients. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , <b>2020</b> , 8, 851-859	3.2	17
141	The prevalence and importance of frailty in heart failure with reduced ejection fraction: an analysis of PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2123-2133	12.3	22
140	Endpoints in Heart Failure Drug Development: History and Future. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 429-440	7.9	16
139	Who and when to clip: that is the question. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 20-22	12.3	0
138	Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock. <i>American Heart Journal</i> , <b>2020</b> , 219, 1-8	4.9	11
137	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 528-538	12.3	16
136	Predictors of Clinical Response to Transcatheter Reduction of Secondary Mitral Regurgitation: The COAPT Trial. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 1007-1014	15.1	10
135	Baseline Functional Capacity and Transcatheter Mitral Valve Repair in Heart Failure With Secondary Mitral Regurgitation. <i>JACC: Cardiovascular Interventions</i> , <b>2020</b> , 13, 2331-2341	5	10
134	Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2175-2186	12.3	8
133	Pulmonary Hypertension in Transcatheter Mitral Valve Repair for Secondary Mitral Regurgitation: The COAPT Trial. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 2595-2606	15.1	9

132	Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 2368-2378	15.1	16
131	Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 961-972	7.9	4
130	Transcatheter Mitral Valve Repair in Patients With and Without Cardiac Resynchronization Therapy: The COAPT Trial. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e007293	7.6	12
129	Impact of COPD on Outcomes After MitraClip for Secondary Mitral Regurgitation: The COAPT Trial. <i>JACC: Cardiovascular Interventions</i> , <b>2020</b> , 13, 2795-2803	5	3
128	Lower Rates of Heart Failure and All-Cause Hospitalizations During Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure: One-Year Outcomes From the CardioMEMS Post-Approval Study. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006863	7.6	51
127	Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2370-2379	12.3	9
126	Impact of Tricuspid Regurgitation on Clinical Outcomes: The COAPT Trial. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 1305-1314	15.1	20
125	Cardiac safety research consortium "shock II" think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock. <i>American Heart Journal</i> , <b>2020</b> , 230, 93-97	4.9	7
124	Apneas of Heart Failure and Phenotype-Guided Treatments: Part One: OSA. <i>Chest</i> , <b>2020</b> , 157, 394-402	5.3	10
123	Long-term efficacy and safety of phrenic nerve stimulation for the treatment of central sleep apnea. <i>Sleep</i> , <b>2019</b> , 42,	1.1	27
122	Echocardiographic Outcomes After Transcatheter Leaflet Approximation in Patients With Secondary Mitral Regurgitation: The COAPT Trial. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 2969-2979	15.1	88
121	Design and rationale for the Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in non-responders and previously untreatable patients (SOLVE-CRT) trial. <i>American Heart Journal</i> , <b>2019</b> , 217, 13-22	4.9	16
120	Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF). <i>American Heart Journal</i> , <b>2019</b> , 214, 18-27	4.9	24
119	Imaging Device Therapy: Essentials for the Imager. <i>Heart Failure Clinics</i> , <b>2019</b> , 15, 305-320	3.3	
118	Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 336-346	7.9	42
117	Design of a "Lean" Case Report Form for Heart Failure Therapeutic Development. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 913-921	7.9	3
116	Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 586-598	7.9	13
115	Phrenic nerve stimulation in patients with central sleep apnea: a single-center experience from pilot and pivotal trials evaluating the remed <sup>2</sup> system. <i>Kardiologia Polska</i> , <b>2019</b> , 77, 553-560	0.9	1

114	Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea: A Pooled Cohort Analysis. <i>Journal of Clinical Sleep Medicine</i> , <b>2019</b> , 15, 1747-1755	3.1	11
113	A Novel Wireless Left Atrial Pressure Monitoring System for Patients with Heart Failure, First Ex-Vivo and Animal Experience. <i>Journal of Cardiovascular Translational Research</i> , <b>2019</b> , 12, 290-298	3.3	15
112	Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 29-40	15.1	86
111	Design and rationale of haemodynamic guidance with CardioMEMS in patients with a left ventricular assist device: the HEMO-VAD pilot study. <i>ESC Heart Failure</i> , <b>2019</b> , 6, 194-201	3.7	24
110	Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 577-587	12.3	22
109	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 888-895	12.3	65
108	Sustained 12 Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea. <i>American Journal of Cardiology</i> , <b>2018</b> , 121, 1400-1408	3	20
107	The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study design. <i>American Heart Journal</i> , <b>2018</b> , 201, 141-148	4.9	15
106	Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 443-453	15.1	22
105	The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 780-791	12.3	47
104	A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. <i>American Heart Journal</i> , <b>2018</b> , 199, 51-58	4.9	7
103	Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease. <i>International Journal of Cardiology</i> , <b>2018</b> , 266, 187-192	3.2	16
102	Pilot Randomized Controlled Trial to Reduce Readmission for Heart Failure Using Novel Tablet and Nurse Practitioner Education. <i>American Journal of Medicine</i> , <b>2018</b> , 131, 974-978	2.4	5
101	Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS Complexes. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 1325-1333	15.1	10
100	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 136-147	12.3	15
99	The Utility of a Wireless Implantable Hemodynamic Monitoring System in Patients Requiring Mechanical Circulatory Support. <i>ASAIO Journal</i> , <b>2018</b> , 64, 301-308	3.6	19
98	Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial. <i>American Heart Journal</i> , <b>2018</b> , 205, 1-11	4.9	55
97	A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 874-883	7.9	91



96	First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF. <i>American Heart Journal</i> , <b>2018</b> , 204, 139-150	4.9	17
95	Interaction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	6	13
94	Transcatheter Mitral-Valve Repair in Patients with Heart Failure. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 2307-2318	59.2	1160
93	Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1746-1754	12.3	41
92	Dose Response of $\beta$ -Blockers in Adrenergic Receptor Polymorphism Genotypes. <i>Circulation Genomic and Precision Medicine</i> , <b>2018</b> , 11, e002210	5.2	3
91	Interatrial Shunting for Heart Failure: Early and Late Results From the First-in-Human Experience With the V-Wave System. <i>JACC: Cardiovascular Interventions</i> , <b>2018</b> , 11, 2300-2310	5	42
90	Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor: Relationship to Mortality in Patients With Chronic Heart Failure. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	54
89	Impact of Practice-Based Management of Pulmonary Artery Pressures in 2000 Patients Implanted With the CardioMEMS Sensor. <i>Circulation</i> , <b>2017</b> , 135, 1509-1517	16.7	81
88	Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac Resynchronization: Results From the REVERSE Trial. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 169-178	7.9	22
87	Evaluation of remote dielectric sensing (ReDS) technology-guided therapy for decreasing heart failure re-hospitalizations. <i>International Journal of Cardiology</i> , <b>2017</b> , 240, 279-284	3.2	61
86	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1956-1964	59.2	185
85	The Role of Implantable Hemodynamic Monitors to Manage Heart Failure. <i>Cardiology Clinics</i> , <b>2017</b> , 35, 273-279	2.5	4
84	Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 2428-2445	15.1	50
83	Patient Perceptions on Facilitating Follow-Up After Heart Failure Hospitalization. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	7
82	Predictors of short-term clinical response to cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1056-1063	12.3	18
81	Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1875-1886	15.1	124
80	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	37
79	Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial. <i>European Heart Journal</i> , <b>2017</b> , 38, 720-726	9.5	17

78	Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 2490-2500	15.1	65
77	Implantable Hemodynamic Monitoring for Heart Failure Patients. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 389-398	15.1	62
76	Evaluating the quality of implantation of percutaneous ventricular restoration device (Parachute®) by cardiac computed tomography. <i>Catheterization and Cardiovascular Interventions</i> , <b>2017</b> , 89, E104-E111	2.7	1
75	Remote haemodynamic-guided care for patients with chronic heart failure: a meta-analysis of completed trials. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 426-433	12.3	34
74	Effect of cardiac resynchronization therapy in patients with diabetes randomized in EchoCRT. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 80-87	12.3	4
73	The Davis Heart and Lung Research Institute: Building a Sustainable Platform for Translation. <i>Circulation Research</i> , <b>2017</b> , 120, 1068-1071	15.7	1
72	Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 204-212	7.9	18
71	Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial. <i>European Heart Journal</i> , <b>2016</b> , 37, 49-59	9.5	30
70	Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. <i>Lancet, The</i> , <b>2016</b> , 388, 974-82	40	96
69	Cardiac computed tomography assessment of the near term impact of percutaneous ventricular restoration therapy (parachute®) on mitral valve geometry. <i>Catheterization and Cardiovascular Interventions</i> , <b>2016</b> , 88, E45-51	2.7	2
68	Pulmonary Artery Pressure-Guided Heart Failure Management Reduces 30-Day Readmissions. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	50
67	Similar hemodynamic decongestion with vasodilators and inotropes: systematic review, meta-analysis, and meta-regression of 35 studies on acute heart failure. <i>Clinical Research in Cardiology</i> , <b>2016</b> , 105, 971-980	6.1	33
66	Current and future developments in the field of central sleep apnoea. <i>Europace</i> , <b>2016</b> , 18, 1123-34	3.9	16
65	Interventions Linked to Decreased Heart Failure Hospitalizations During Ambulatory Pulmonary Artery Pressure Monitoring. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 333-44	7.9	82
64	Current treatment approaches and trials in central sleep apnea. <i>International Journal of Cardiology</i> , <b>2016</b> , 206 Suppl, S22-7	3.2	7
63	Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. <i>Lancet, The</i> , <b>2016</b> , 387, 453-61	40	296
62	Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 1521-32	59.2	159
61	Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , <b>2016</b> , 28, 320-328	1.7	15



60	Transvenous stimulation of the phrenic nerve for the treatment of central sleep apnoea: 12 months experience with the remedus System. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1386-1393	12.3	32
59	The role of implantable hemodynamic monitors to manage heart failure. <i>Heart Failure Clinics</i> , <b>2015</b> , 11, 183-9	3.3	5
58	The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. <i>European Heart Journal</i> , <b>2015</b> , 36, 1983-9	9.5	48
57	Limitations of right heart catheterization in the diagnosis and risk stratification of patients with pulmonary hypertension related to left heart disease: insights from a wireless pulmonary artery pressure monitoring system. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, 438-47	5.8	21
56	Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 487-496	7.9	139
55	MG53-mediated cell membrane repair protects against acute kidney injury. <i>Science Translational Medicine</i> , <b>2015</b> , 7, 279ra36	17.5	70
54	D-ribose aids heart failure patients with preserved ejection fraction and diastolic dysfunction: a pilot study. <i>Therapeutic Advances in Cardiovascular Disease</i> , <b>2015</b> , 9, 56-65	3.4	19
53	Center of excellence for mobile sensor data-to-knowledge (MD2K). <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2015</b> , 22, 1137-42	8.6	38
52	Long-Term Extrapolation of Clinical Benefits Among Patients With Mild Heart Failure Receiving Cardiac Resynchronization Therapy: Analysis of the 5-Year Follow-Up From the REVERSE Study. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 691-700	7.9	5
51	Phrenic nerve stimulation for the treatment of central sleep apnea. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 360-369	7.9	89
50	A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with moderately reduced left ventricular ejection fraction and a narrow QRS duration: study rationale and design. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 16-23	3.3	25
49	Pulmonary hypertension related to left heart disease: insight from a wireless implantable hemodynamic monitor. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, 329-37	5.8	47
48	The Aliskiren Trial to Minimize Outcomes in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1075-83	12.3	16
47	Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF). <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 479-88	3.3	50
46	Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1066-74	12.3	62
45	Mechanisms and clinical consequences of untreated central sleep apnea in heart failure. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 72-84	15.1	86
44	Sleep disordered breathing and post-discharge mortality in patients with acute heart failure. <i>European Heart Journal</i> , <b>2015</b> , 36, 1463-9	9.5	152
43	Population Study of Urban, Rural, and Semiurban Regions for the Detection of Endovascular Disease and Prevalence of Risk Factors and Holistic Intervention Study: Rationale, Study Design, and Baseline Characteristics of PURSE-HIS. <i>Global Heart</i> , <b>2015</b> , 10, 281-9	2.9	7

42	Percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure: three-year outcomes of the PARACHUTE first-in-human study. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 752-8	7.6	44
41	Ambulatory extra-aortic counterpulsation in patients with moderate to severe chronic heart failure. <i>JACC: Heart Failure</i> , <b>2014</b> , 2, 526-33	7.9	17
40	Novel non-pharmacological approaches to heart failure. <i>Journal of Cardiovascular Translational Research</i> , <b>2014</b> , 7, 263-5	3.3	6
39	Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 935-44	7.6	256
38	Current challenges for clinical trials of cardiovascular medical devices. <i>International Journal of Cardiology</i> , <b>2014</b> , 175, 30-7	3.2	31
37	Trials of implantable monitoring devices in heart failure: which design is optimal?. <i>Nature Reviews Cardiology</i> , <b>2014</b> , 11, 576-85	14.8	27
36	Abstract 16744: Impact of Wireless Pulmonary Artery Pressure Monitoring on Heart Failure Hospitalizations and All-Cause 30-Day Readmissions in Medicare-Eligible Patients With NYHA Class III Heart Failure: Results From the CHAMPION Trial. <i>Circulation</i> , <b>2014</b> , 130,	16.7	4
35	Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 2000-2007	15.1	136
34	Prevention of atrial fibrillation by bucindolol is dependent on the beta <sub>1</sub> Arg/Gly adrenergic receptor polymorphism. <i>JACC: Heart Failure</i> , <b>2013</b> , 1, 338-344	7.9	39
33	Devices in the management of advanced, chronic heart failure. <i>Nature Reviews Cardiology</i> , <b>2013</b> , 10, 98-110	14.8	44
32	Remote heart failure monitoring. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2013</b> , 15, 556-64	2.1	2
31	Disease management: remote monitoring in heart failure patients with implantable defibrillators, resynchronization devices, and haemodynamic monitors. <i>Europace</i> , <b>2013</b> , 15 Suppl 1, i40-i46	3.9	31
30	Burden of atrial fibrillation and poor rate control detected by continuous monitoring and the risk for heart failure hospitalization. <i>American Heart Journal</i> , <b>2012</b> , 164, 616-24	4.9	36
29	Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. <i>Kidney International</i> , <b>2012</b> , 82, 1215-22	9.9	27
28	Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. <i>Kidney International</i> , <b>2012</b> , 82, 1223-30	9.9	25
27	Combinatorial pharmacogenetic interactions of bucindolol and $\beta_1$ , $\beta_2$ adrenergic receptor polymorphisms. <i>PLoS ONE</i> , <b>2012</b> , 7, e44324	3.7	48
26	CHAMPION trial rationale and design: the long-term safety and clinical efficacy of a wireless pulmonary artery pressure monitoring system. <i>Journal of Cardiac Failure</i> , <b>2011</b> , 17, 3-10	3.3	117
25	Hemodynamic factors associated with acute decompensated heart failure: part 2--use in automated detection. <i>Journal of Cardiac Failure</i> , <b>2011</b> , 17, 366-73	3.3	21

24	Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. <i>Lancet, The</i> , <b>2011</b> , 377, 658-66	40	982
23	Intrathoracic impedance vs daily weight monitoring for predicting worsening heart failure events: results of the Fluid Accumulation Status Trial (FAST). <i>Congestive Heart Failure</i> , <b>2011</b> , 17, 51-5		155
22	Nesiritide in acute decompensated heart failure: a pooled analysis of randomized controlled trials. <i>Clinical Cardiology</i> , <b>2010</b> , 33, 484-9	3.3	12
21	Treatment of anemia with darbepoetin alfa in heart failure. <i>Congestive Heart Failure</i> , <b>2010</b> , 16, 87-95		4
20	Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. <i>Clinical and Translational Science</i> , <b>2010</b> , 3, 249-53	4.9	29
19	Pharmacologic therapies across the continuum of left ventricular dysfunction. <i>American Journal of Cardiology</i> , <b>2008</b> , 102, 21G-28G	3	18
18	Switching to evidence-based once-daily beta-blockers for improved adherence to medication across the continuum of post-myocardial infarction left ventricular dysfunction and heart failure. <i>Congestive Heart Failure</i> , <b>2008</b> , 14, 272-80		2
17	Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 347-56	15.1	394
16	Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 1834-1843	15.1	851
15	A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. <i>American Heart Journal</i> , <b>2008</b> , 156, 641-648.e1	4.9	30
14	Optimization of Cardiac Resynchronization Devices Using Acoustic Cardiography: A Comparison to Echocardiography. <i>Congestive Heart Failure</i> , <b>2006</b> , 12, 25-31		5
13	Cardiac resynchronization therapy is important for all patients with congestive heart failure and ventricular dyssynchrony. <i>Circulation</i> , <b>2006</b> , 114, 2692-8; discussion 2698	16.7	6
12	In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 46, 57-64	15.1	608
11	Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers. <i>Congestive Heart Failure</i> , <b>2005</b> , 11, 59-64		15
10	Cardiac Resynchronization Therapy in Heart Failure. <i>Annals of Internal Medicine</i> , <b>2005</b> , 142, 307	8	1
9	Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. <i>Circulation</i> , <b>2004</b> , 110, 2864-8	16.7	393
8	Preventing cardiovascular events in patients with diabetes mellitus. <i>American Journal of Medicine</i> , <b>2004</b> , 116 Suppl 5A, 39S-46S	2.4	14
7	Practical considerations for switching beta-blockers in heart failure patients. <i>Reviews in Cardiovascular Medicine</i> , <b>2004</b> , 5 Suppl 1, S36-44	3.9	

6	Cardiac resynchronization therapy for the management of chronic heart failure. <i>The American Heart Hospital Journal</i> , <b>2003</b> , 1, 55-61		10
5	Cardiac resynchronization therapy for heart failure. <i>Circulation</i> , <b>2003</b> , 108, 2596-603	16.7	241
4	Cardiac resynchronization therapy: a review of clinical trials and criteria for identifying the appropriate patient. <i>Reviews in Cardiovascular Medicine</i> , <b>2003</b> , 4 Suppl 2, S30-7	3.9	7
3	Diabetes, hypertension, and renal insufficiency in post-myocardial infarction cardiovascular risk. <i>Reviews in Cardiovascular Medicine</i> , <b>2003</b> , 4 Suppl 3, S30-6	3.9	1
2	Comprehensive Pharmacologic Management Strategies for Heart Failure15-34		1
1	Clinical Trials Supporting Current Indications for CRT261-276		